The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rumyantsev A.G.

Dmitry Rogachev National Medical Research Center for Children’s Hematology, Oncology and Immunology, Moscow, Russia

Kutsev S.I.

Research Centre for Medical Genetics named after N.P. Bochkov, Moscow, Russia

Namazova-Baranova L.S.

Scientific and Clinical Center No. 2 of the Russian Scientific Center for Surgery named after Academician B.V. Petrovsky, Moscow, Russia

Zhukova O.V.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia;
Peoples’ Friendship University of Russia, Moscow, Russia

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Zyryanov S.K.

Peoples’ Friendship University of Russia, Moscow, Russia

Kotalevskaya Yu.Yu.

Research Clinical Institute of Childhood of the Moscow Region, Mytishchi, Russia

Porshina O.V.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Prodeus A.P.

National Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russia

Raznatovskiy K.I.

North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia

Smirnova N.S.

PROVE LLC, Saint Petersburg, Russia

Shkolnikova T.V.

Saint Petersburg City Dermatovenerologic Dispensary, Saint Petersburg, Russia

New pathogenetic approaches to the treatment of wounds in congenital epidermolysis bullosa

Authors:

Rumyantsev A.G., Kutsev S.I., Namazova-Baranova L.S., Zhukova O.V., Potekaev N.N., Zyryanov S.K., Kotalevskaya Yu.Yu., Porshina O.V., Prodeus A.P., Raznatovskiy K.I., Smirnova N.S., Shkolnikova T.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2026;25(1): 104‑111

DOI: 10.17116/klinderma202625011104

Read: 393 times

Download PDF (RU)
Contact the author
Table of contents

NEW PATHOGENETIC APPROACHES TO THE TREATMENT OF WOUNDS IN CONGENITAL EPIDERMOLYSIS BULLOSA
NEW PATHOGENETIC APPROACHES TO THE TREATMENT OF WOUNDS IN CONGENITAL EPIDERMOLYSIS BULLOSA

To cite this article:

Rumyantsev AG, Kutsev SI, Namazova-Baranova LS, et al. New pathogenetic approaches to the treatment of wounds in congenital epidermolysis bullosa. Russian Journal of Clinical Dermatology and Venereology. 2026;25(1):104‑111. (In Russ.)
https://doi.org/10.17116/klinderma202625011104

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Congenital epidermolysis bullosa is a group of rare, incurable, genetically heterogeneous diseases that are characterized by the fragility of the skin and mucous membranes with the formation of bullae and erosions in response to minor injury. This severe disease is divided into 4 major types and is often accompanied by multisystem complications such as anemia, gastrointestinal tract lesions, growth retardation and high risk of developing squamous cell carcinoma, which significantly deteriorates the quality of life of patients and the prognosis of disease. Gel containing a complex of triterpenes is the only pathogenetic drug for the treatment of wounds in dystrophic and junctional epidermolysis bullosa registered in Russia. The mechanism of action of the drug is aimed at the key elements of pathogenesis: modulation of inflammation, stimulation of keratinocyte migration and stabilization of dermal-epidermal junction. The international EASE study has shown that this gel significantly increases the probability of complete wound healing, shortens dressing time and reduces pain in patients. Based on these data, Russian experts have formed a consensus position in which they emphasize the clinical significance of the obtained results and predict that the drug will occupy an important place in the baseline therapy of the disease, marking the transition from a purely symptomatic approach to targeted pathogenetic exposure. The inclusion of this approach in clinical guidelines is considered as a key step to improve the effectiveness of care for patients with congenital epidermolysis bullosa in Russia.

Keywords:

epidermolysis bullosa
complex of triterpenes
pathogenetic therapy of CEB

Authors:

Rumyantsev A.G.

Dmitry Rogachev National Medical Research Center for Children’s Hematology, Oncology and Immunology, Moscow, Russia

Kutsev S.I.

Research Centre for Medical Genetics named after N.P. Bochkov, Moscow, Russia

Namazova-Baranova L.S.

Scientific and Clinical Center No. 2 of the Russian Scientific Center for Surgery named after Academician B.V. Petrovsky, Moscow, Russia

Zhukova O.V.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia;
Peoples’ Friendship University of Russia, Moscow, Russia

Potekaev N.N.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Zyryanov S.K.

Peoples’ Friendship University of Russia, Moscow, Russia

Kotalevskaya Yu.Yu.

Research Clinical Institute of Childhood of the Moscow Region, Mytishchi, Russia

Porshina O.V.

Moscow Scientific and Practical Center of Dermatovenerology and Cosmetology, Moscow, Russia

Prodeus A.P.

National Medical Research Center of Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow, Russia

Raznatovskiy K.I.

North-Western State Medical University named after I.I. Mechnikov of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia

Smirnova N.S.

PROVE LLC, Saint Petersburg, Russia

Shkolnikova T.V.

Saint Petersburg City Dermatovenerologic Dispensary, Saint Petersburg, Russia

Received:

19.12.2025

Accepted:

01.02.2026

Close metadata

References:

  1. Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, Fine JD, Heagerty A, Hovnanian A, Marinkovich MP, Martinez AE, McGrath JA, Moss C, Murrell DF, Palisson F, Schwieger-Briel A, Sprecher E, Tamai K, Uitto J, Woodley DT, Zambruno G, Mellerio JE. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020 Oct;183(4):614-627.  https://doi.org/10.1111/bjd.18921
  2. Potekaev NN, Zhukova OV, Porshina OV, Petunina VV, Tsygankova EI, Frigo NV, Berezovskaya EM. Epidemiology of inherited epidermolysis bullosa in the Russian Federation. Russian Journal of Clinical Dermatology and Venereology. 2025;24(5):574-582. (In Russ.). https://doi.org/10.17116/klinderma202524051574
  3. Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, Gillon J, Patel D, Rudin D. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021 Apr 13;16(1):175.  https://doi.org/10.1186/s13023-021-01811-7
  4. Bruckner AL, Losow M, Wisk J, Patel N, Reha A, Lagast H, Gault J, Gershkowitz J, Kopelan B, Hund M, Murrell DF. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020 Jan 3;15(1):1.  https://doi.org/10.1186/s13023-019-1279-y
  5. Jeon IK, On HR, Kim SC. Quality of Life and Economic Burden in Recessive Dystrophic Epidermolysis Bullosa. Ann Dermatol. 2016 Feb;28(1):6-14.  https://doi.org/10.5021/ad.2016.28.1.6
  6. Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, de Souza MP, Murrell DF, Marinkovich MP, Tang JY. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. J Am Acad Dermatol. 2021 Nov;85(5):1161-1167. https://doi.org/10.1016/j.jaad.2020.03.028
  7. Hwang SJE, Daniel BS, Fergie B, Davey J, Murrell DF. Prevalence of anemia in patients with epidermolysis bullosa registered in Australia. Int J Womens Dermatol. 2015 Feb 18;1(1):37-40.  https://doi.org/10.1016/j.ijwd.2014.12.001
  8. Freeman EB, Köglmeier J, Martinez AE, Mellerio JE, Haynes L, Sebire NJ, Lindley KJ, Shah N. Gastrointestinal complications of epidermolysis bullosa in children. Br J Dermatol. 2008 Jun;158(6):1308-1314. https://doi.org/10.1111/j.1365-2133.2008.08507.x
  9. Haynes L. Nutrition for children with epidermolysis bullosa. Dermatol Clin. 2010 Apr;28(2):289-301.  https://doi.org/10.1016/j.det.2010.01.010
  10. Cuadrado-Corrales N, Lopez-de-Andres A, Hernández-Barrera V, Carabantes-Alarcon D, Zamorano-Leon JJ, Omaña-Palanco R, Del-Barrio JL, De-Miguel-Díez J, Jimenez-Garcia R, Montoya JJ. Clinical Characteristics and Outcomes of Patients Hospitalized with Epidermolysis Bullosa: A Retrospective Population-Based Observational Study in Spain (2016-2021). Biomedicines. 2023 Sep 20;11(9):2584. https://doi.org/10.3390/biomedicines11092584
  11. Baardman R, Yenamandra VK, Duipmans JC, Pasmooij AMG, Jonkman MF, van den Akker PC, Bolling MC. Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed? J Eur Acad Dermatol Venereol. 2021 Apr; 35(4):995-1006. https://doi.org/10.1111/jdv.17012
  12. Fine JD, Johnson LB, Weiner M, Suchindran C. Cause-specific risks of childhood death in inherited epidermolysis bullosa. J Pediatr. 2008 Feb; 152(2):276-280.  https://doi.org/10.1016/j.jpeds.2007.06.039
  13. Paller AS, Pope E, Rudin D, Malyala A, Ramsdell D, Johnson R, Landy H, Murrell DF; DEB Investigators. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022 Aug 13;17(1):314.  https://doi.org/10.1186/s13023-022-02461-z
  14. Danescu S, Negrutiu M, Has C. Treatment of Epidermolysis Bullosa and Future Directions: A Review. Dermatol Ther (Heidelb). 2024 Aug;14(8): 2059-2075. https://doi.org/10.1007/s13555-024-01227-8
  15. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215064s000lbl.pdf 
  16. https://www.ema.europa.eu/en/medicines/human/EPAR/filsuvez
  17. https://www.ema.europa.eu/en/medicines/human/EPAR/vyjuvek
  18. https://www.fda.gov/media/186511/download?attachment
  19. https://www.fda.gov/media/168350/download?attachment
  20. Obshchaya kharakteristika lekarstvennogo preparata Fil’zuves® LP-№(012364)-(RG-RU) ot 07.11.2025. (In Russ.).
  21. Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming. Drug Resist Updat. 2021 Jan;54:100742. https://doi.org/10.1016/j.drup.2020.100742
  22. Klinicheskie rekomendatsii MZ RF «Khronicheskaya serdechnaya nedostatochnost’», 2024. (In Russ.).
  23. Alekberova ZS, Nasonov EL. Prospects for using colchicine in medicine: New evidence. Rheumatology Science and Practice. 2020;58(2):183-190. (In Russ.). https://doi.org/10.14412/1995-4484-2020-183-190
  24. Goddard ZR, Searcey M, Osbourn A. Advances in triterpene drug discovery. Trends Pharmacol Sci. 2024 Nov;45(11):964-968.  https://doi.org/10.1016/j.tips.2024.10.003
  25. Cianfarani F, Zambruno G, Castiglia D, Odorisio T. Pathomechanisms of Altered Wound Healing in Recessive Dystrophic Epidermolysis Bullosa. Am J Pathol. 2017 Jul;187(7):1445-1453. https://doi.org/10.1016/j.ajpath.2017.03.003
  26. Schwieger-Briel A, Ott H, Kiritsi D, Laszczyk-Lauer M, Bodemer C. Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa. Dermatol Ther. 2019 Jul;32(4):e12983. https://doi.org/10.1111/dth.12983
  27. Ebeling S, Naumann K, Pollok S, Wardecki T, Vidal-Y-Sy S, Nascimento JM, Boerries M, Schmidt G, Brandner JM, Merfort I. From a traditional medicinal plant to a rational drug: understanding the clinically proven wound healing efficacy of birch bark extract. PLoS One. 2014 Jan 22;9(1):e86147. https://doi.org/10.1371/journal.pone.0086147
  28. Gretzmeier C, Athanasiou I, Laszczyk-Lauer M, Kiritsi D, Cassidy A, Nystrom A. Effect of triterpene extract on skin cohesion in epidermolysis bullosa. 2024. Presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, The Netherlands. September 25–28, P1944.
  29. Woelfle U, Laszczyk MN, Kraus M, Leuner K, Kersten A, Simon-Haarhaus B, Scheffler A, Martin SF, Müller WE, Nashan D, Schempp CM. Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol. 2010 Jan;130(1):113-123.  https://doi.org/10.1038/jid.2009.248
  30. Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, Löwe S, Davis C, Sumeray M, Bruckner AL, Murrell DF; EASE investigators. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023 Jan 23;188(1):12-21.  https://doi.org/10.1093/bjd/ljac001
  31. Bruckner AL, Murrell D, Lee LW, Sprecher E, Kiritsi D, Maher L, Löwe S, Donovan M, Kern JS; EASE investigators. Reduction in Dressing Change Burden in Patients With Epidermolysis Bullosa-Impact of Oleogel-S10. J Dermatol. 2025 Sep;52(9):1447-1451. https://doi.org/10.1111/1346-8138.17884
  32. Murrell DF, Bodemer C, Bruckner AL, Cunningham T, Davis C, Fernández MF, Kiritsi D, Maher L, Sprecher E, Torres-Pradilla M, Kern JS. Long-term safety and efficacy of Oleogel-S10 (birch bark extract) in epidermolysis bullosa: 24-month results from the phase III EASE study. Br J Dermatol. 2025 May 19;192(6):1007-1017. https://doi.org/10.1093/bjd/ljaf022
  33. Torres Pradilla M, Álvarez E, Novoa M, Lozano I, Trujillo M. Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years. Adv Ther. 2024 Feb;41(2):867-877. Epub 2024 Jan 3. Erratum in: Adv Ther. 2025 Feb;42(2):1290. https://doi.org/10.1007/s12325-023-02749-x
  34. Davidovic M, Gewert S, Kiritsi D, Has C. Oleogel-S10 for chronic wounds in EB: preliminary result of the real-world experience. Abstract N°: 3496. Presented at the EADV Congress 2023, Berlin, Germany. 11—14 October 2023.
  35. Drenovska K, Vassileva S. Birch bark extract in the treatment of dystrophic epidermolysis bullosa. Poster presented at the WCRSD Congress 2024, Paris, France. 12—14 June 2024.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.